Chemed Corporation (NYSE:CHE) Stock Has Average Target Price of $554.60

Shares of Chemed Corporation (NYSE:CHE) have been given a consensus rating of “Hold” by the seven analysts that are presently covering the firm, Marketbeat Ratings reports. Five investment analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $554.60.

Several brokerages have issued reports on CHE. Bank of America reaffirmed a “neutral” rating on shares of Chemed in a report on Wednesday, July 29th. Oppenheimer lifted their target price on Chemed from $500.00 to $590.00 and gave the stock an “outperform” rating in a research report on Friday, July 31st. Weiss Ratings raised Chemed from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday, October 8th. UBS Group assumed coverage on Chemed in a research report on Friday, September 25th. They issued a “buy” rating and a $650.00 target price for the company. Finally, Royal Bank Of Canada raised their price target on Chemed from $436.00 to $548.00 and gave the stock a “sector perform” rating in a research note on Thursday, July 30th.

Chemed Stock Up 0.3%

CHE stock opened at $514.51 on Tuesday. The stock has a market cap of $6.72 billion, a P/E ratio of 23.91, a PEG ratio of 2.06 and a beta of 0.51. The company has a current ratio of 0.91, a quick ratio of 0.89 and a debt-to-equity ratio of 0.17. Chemed has a twelve month low of $365.20 and a twelve month high of $557.00. The company’s 50 day moving average is $518.37 and its two-hundred day moving average is $470.82.

Chemed (NYSE:CHE) last issued its earnings results on Tuesday, July 28th. The company reported $6.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.60 by $0.46. The business had revenue of $673.25 million during the quarter, compared to analysts’ expectations of $665.04 million. Chemed had a net margin of 10.60% and a return on equity of 31.77%. The company’s revenue for the quarter was up 8.8% on a year-over-year basis. During the same quarter in the prior year, the business posted $4.27 EPS. Chemed has set its FY 2026 guidance at 25.000-25.750 EPS. Research analysts expect that Chemed will post 23.55 earnings per share for the current fiscal year.

Chemed Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, September 3rd. Investors of record on Monday, August 17th were given a $0.70 dividend. This is a positive change from Chemed’s previous quarterly dividend of $0.60. The ex-dividend date was Monday, August 17th. This represents a $2.80 annualized dividend and a yield of 0.5%. Chemed’s payout ratio is currently 14.06%.

Insiders Place Their Bets

In related news, EVP Spencer S. Lee sold 1,000 shares of the firm’s stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $541.04, for a total transaction of $541,040.00. Following the transaction, the executive vice president owned 13,912 shares of the company’s stock, valued at $7,526,948.48. This trade represents a 6.71% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Kevin J. Mcnamara sold 2,000 shares of the firm’s stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $539.51, for a total value of $1,079,020.00. Following the transaction, the chief executive officer directly owned 70,418 shares in the company, valued at approximately $37,991,215.18. This represents a 2.76% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 9,190 shares of company stock valued at $4,833,160. Insiders own 3.33% of the company’s stock.

Institutional Trading of Chemed

Hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. acquired a new position in shares of Chemed in the second quarter valued at approximately $691,290,000. First Trust Advisors LP raised its position in Chemed by 24.7% during the 1st quarter. First Trust Advisors LP now owns 236,392 shares of the company’s stock worth $89,295,000 after buying an additional 46,791 shares during the last quarter. Copeland Capital Management LLC lifted its stake in shares of Chemed by 1.3% in the 3rd quarter. Copeland Capital Management LLC now owns 146,833 shares of the company’s stock worth $74,162,000 after acquiring an additional 1,826 shares during the period. Bank of America Corp DE acquired a new stake in shares of Chemed in the 2nd quarter worth $48,255,000. Finally, Caisse de depot et placement du Quebec acquired a new stake in shares of Chemed in the 2nd quarter worth $44,309,000. 95.85% of the stock is owned by institutional investors and hedge funds.

Chemed Company Profile

Chemed Corporation is a diversified services company headquartered in Cincinnati, Ohio. Its operations are organized through two principal businesses: VITAS Healthcare and Roto-Rooter.

VITAS Healthcare provides hospice and palliative care for patients with advanced illnesses. Its services include clinical care, pain and symptom management, emotional and spiritual support, and assistance for patients and their families in homes, hospice residences, hospitals, nursing facilities, and other care settings.